Raloxifene

Raloxifene Dragon Pharma — Overview

Raloxifene Dragon Pharma is a second-generation selective estrogen receptor modulator (SERM) supplied at 60 mg per tablet. Its primary application in performance protocols is the treatment and prevention of gynecomastia — and specifically the reversal of existing glandular breast tissue, where clinical evidence consistently shows raloxifene 60 mg/day outperforms tamoxifen (Nolvadex) 20 mg/day in reducing gynecomastia volume. Like all SERMs, raloxifene also stimulates LH and FSH by blocking estrogen's negative feedback on the hypothalamus-pituitary axis, making it a functional PCT agent.

The defining pharmacological difference between raloxifene and first-generation SERMs like tamoxifen is tissue selectivity profile. Tamoxifen has partial agonist activity in some tissues (liver, endometrium) that can elevate SHBG and introduce estrogenic side effects; raloxifene has a cleaner antagonist profile in breast tissue with no meaningful pro-estrogenic activity at the uterus. Raloxifene does not reduce circulating estradiol (E2) — it blocks the estrogen receptor in breast tissue rather than inhibiting aromatization — so it is used alongside aromatase inhibitors when the goal is both preventing new estrogen-driven tissue development and reversing existing glandular mass. Available at Steroid Warehouse at 60 mg/tab, one tablet per day covers standard PCT and gynecomastia reversal protocols.

About the Compound: Raloxifene

Raloxifene is a benzothiophene-derived SERM that binds the estrogen receptor (ER) with high affinity and produces tissue-selective agonist or antagonist effects depending on the cell type. In breast tissue and the hypothalamus, raloxifene acts as an ER antagonist: it displaces estradiol from the receptor and blocks the downstream transcriptional effects of estrogen, which is the mechanism underlying both its gynecomastia-reducing activity and its LH/FSH-stimulating effect in PCT. In bone and the cardiovascular system (lipid metabolism), raloxifene acts as an ER agonist, which drives its FDA-approved clinical indications in osteoporosis.

The critical mechanistic difference from aromatase inhibitors (Aromasin, Letrozole, Anastrozole) is the point of intervention: aromatase inhibitors reduce estradiol production upstream by blocking the aromatase enzyme; raloxifene does not change circulating E2 levels at all — it blocks what E2 does at the receptor in target tissues. This means raloxifene does not produce the joint pain, mood decline, or libido loss associated with E2 over-suppression, but it also cannot address the systemic consequences of excess circulating E2 (water retention, blood pressure elevation) that an AI would prevent. For gynecomastia specifically, receptor blockade is the targeted intervention: the breast gland tissue must be deprived of its ER signaling, which is precisely what raloxifene accomplishes.

Raloxifene has a half-life of approximately 28 hours, supporting once-daily oral dosing with stable plasma levels. At 60 mg/day, it is the standard dose for both PCT and gynecomastia protocols; at 120 mg/day it is used for accelerated reversal of established gynecomastia tissue.

What Raloxifene Does

• Reverses existing gynecomastia glandular tissue — raloxifene's primary and most clinically documented performance use is the reversal of established gynecomastia; by blocking estrogen receptors in breast glandular tissue, it deprives the tissue of the estrogenic signal required to maintain and grow the gland; clinical studies comparing raloxifene 60 mg/day to tamoxifen 20 mg/day in pubertal gynecomastia consistently show greater reduction in glandular volume with raloxifene; the effect requires 8–12 weeks of consistent daily use; it is most effective on softer, more recent glandular tissue and less effective on older fibrotic tissue that has already calcified
• Prevents new estrogen-driven breast gland development — on a cycle where E2 is elevated, raloxifene 60 mg/day blocks the estrogen receptor in breast tissue and prevents the initial glandular stimulation that leads to gynecomastia; this prevention mechanism makes it suitable as an on-cycle gynecomastia protocol for users who cannot tolerate or choose not to use an aromatase inhibitor; it does not address the systemic consequences of elevated E2 (water retention, blood pressure) — only breast tissue ER blockade
• Stimulates LH and FSH for PCT — raloxifene blocks estrogen receptors in the hypothalamus and pituitary, removing E2's negative feedback on GnRH and gonadotropin release; the result is increased LH and FSH secretion, which stimulates Leydig cell testosterone production and restores the HPG axis following AAS-induced suppression; the LH/FSH stimulation is clinically equivalent to tamoxifen at comparable doses; for athletes who have used high-aromatizing cycles and want a SERM that simultaneously stimulates LH/FSH recovery and protects against residual E2-driven gynecomastia, raloxifene covers both goals in one compound
• No E2 over-suppression risk — because raloxifene acts at the receptor level rather than upstream at aromatase, circulating estradiol concentrations are unchanged; joint lubrication, mood stability, libido, and bone mineralization that depend on systemic E2 are preserved during raloxifene use; this contrasts with AI use, where aggressive E2 reduction produces measurable physiological deficits; raloxifene can be run on a cycle or in PCT without the concern of pushing E2 below the functional threshold
• No retinal toxicity risk (unlike tamoxifen) — tamoxifen at long-term high doses carries a documented risk of retinal toxicity and keratopathy; raloxifene does not share this profile; for athletes who require extended SERM therapy for persistent gynecomastia (8–12 weeks or more) or who use SERMs across multiple cycles, raloxifene's cleaner safety profile at the eye is a practical clinical advantage

Who It's For

• Users with established gynecomastia that did not respond adequately to Nolvadex — tamoxifen 20 mg/day is the most commonly used first-line gynecomastia SERM because of familiarity and availability; when it fails to produce sufficient reduction, raloxifene 60–120 mg/day is the appropriate escalation; the clinical evidence for raloxifene's superiority in glandular volume reduction makes it the preferred choice when gyno reversal — rather than just prevention — is the goal; it is also a reasonable first-line choice for any user who has an established gynecomastia nodule they want to address
• Users who want a single compound covering both PCT and gynecomastia management — Nolvadex for PCT + separate gyno management requires juggling two SERMs or adding an AI; raloxifene at 60 mg/day handles LH/FSH stimulation for testosterone recovery while simultaneously maintaining breast tissue ER blockade; for users whose cycle involved high aromatization (testosterone, Dianabol) and who experienced some gynecomastia development, raloxifene is the most efficient single-compound PCT option
• What differentiates Raloxifene from similar alternatives: compared to Nolvadex (tamoxifen), raloxifene has better clinical evidence for gynecomastia reversal, no retinal toxicity risk, and does not elevate SHBG through liver agonism; Nolvadex has longer PCT track record and is generally better documented for LH/FSH stimulation at higher doses; compared to Aromasin (exemestane), raloxifene blocks the ER while Aromasin eliminates the E2 signal upstream; Aromasin is superior for controlling systemic E2 effects; raloxifene is superior for protecting breast tissue specifically without affecting systemic E2; compared to Clomid (clomiphene), Clomid produces stronger gonadotropin stimulation but with more frequent side effects (visual disturbances, mood swings); raloxifene produces reliable LH/FSH recovery with a more manageable side effect profile
• Users who should choose something else: users who need aggressive systemic E2 reduction (water retention, BP from high-dose aromatizing cycles) should use an AI, not raloxifene; if the only goal is PCT with no gyno concern, Nolvadex or Clomid are equally effective with more PCT-specific data; users with a personal or family history of venous thromboembolism should assess thromboembolic risk before using any SERM

Raloxifene vs Alternatives

Protocols

Side Effects & Management

Bloodwork Monitoring

Tapering & Discontinuation

Raloxifene at 60 mg/day for a standard 4-week PCT does not require tapering — discontinuation is abrupt at the end of the protocol. For longer gynecomastia reversal protocols (8–12 weeks), the same applies: stop at the end of the planned duration. There is no rebound gynecomastia effect from stopping raloxifene once the primary AAS cycle has cleared and E2 has normalized. The key discontinuation rules are:

Practical Summary

References